Compare CHR & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHR | INM |
|---|---|---|
| Founded | 2016 | 1981 |
| Country | China | Canada |
| Employees | 116 | 13 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.1M |
| IPO Year | N/A | 2020 |
| Metric | CHR | INM |
|---|---|---|
| Price | $1.78 | $1.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 43.8K | 19.8K |
| Earning Date | 03-23-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,942,633.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.01 | ★ N/A |
| Revenue Growth | N/A | ★ 7.50 |
| 52 Week Low | $0.03 | $0.58 |
| 52 Week High | $2.71 | $7.98 |
| Indicator | CHR | INM |
|---|---|---|
| Relative Strength Index (RSI) | 53.89 | 85.22 |
| Support Level | $0.07 | $1.09 |
| Resistance Level | $1.97 | $2.37 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 50.62 | 72.46 |
Cheer Holding Inc is a provider of next generation mobile internet infrastructure and platform services in China. It is engaged in building a digital ecosystem that integrates platforms, applications, technology, and industry into a cohesive system, thereby creating a new, open business environment that leverages AI technology. Its portfolio includes various products and services, such as Polaris Intelligent Cloud, CHEERS Telepathy, CHEERS Open Platform, CHEERS Video, CHEERS e-Mall, CheerCar, CheerChat, CHEERS Fresh Group-Buying E-commerce Platform, Digital Innovation Research Institute, CHEERS Livestreaming, variety show series, IP short video matrix, and more.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.